EBF vs. BMY
EBF (Ennis, Inc.) and BMY (Bristol-Myers Squibb Company) are both stocks. EBF operates in Business Equipment & Supplies (Industrials), while BMY operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, EBF returned 7.18%/yr vs 0.72%/yr for BMY. At a 0.18 correlation, their price movements are largely independent.
Performance
EBF vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, EBF achieves a 20.14% return, which is significantly higher than BMY's 10.36% return. Over the past 10 years, EBF has outperformed BMY with an annualized return of 7.18%, while BMY has yielded a comparatively lower 0.72% annualized return.
EBF
- 1D
- -0.52%
- 1M
- 1.68%
- 6M
- 15.78%
- YTD
- 20.14%
- 1Y
- 20.61%
- 3Y*
- 10.07%
- 5Y*
- 7.77%
- 10Y*
- 7.18%
BMY
- 1D
- -0.62%
- 1M
- 1.93%
- 6M
- 5.32%
- YTD
- 10.36%
- 1Y
- 28.77%
- 3Y*
- 1.83%
- 5Y*
- 1.02%
- 10Y*
- 0.72%
EBF vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
EBF Ennis, Inc. | 20.14% | -9.96% | 12.59% | 3.64% | 19.38% | 14.78% | -13.46% | 17.54% | -2.77% | 24.65% |
BMY Bristol-Myers Squibb Company | 10.36% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Correlation
The correlation between EBF and BMY is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.21 |
Correlation (All Time) Calculated using the full available price history since Sep 24, 1987 | 0.18 |
Fundamentals
EBF:
$527.47M
BMY:
$117.58B
EBF:
$1.65
BMY:
$3.56
EBF:
12.60
BMY:
16.15
EBF:
0.90
BMY:
0.92
EBF:
1.37
BMY:
2.42
EBF:
1.71
BMY:
5.86
EBF:
$393.82M
BMY:
$48.48B
EBF:
$121.26M
BMY:
$33.33B
EBF:
$71.61M
BMY:
$13.34B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
EBF vs. BMY — Risk / Return Rank
EBF
BMY
EBF vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ennis, Inc. (EBF) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| EBF | BMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.05 | ||
| Sortino ratioReturn per unit of downside risk | -0.22 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.17 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | 1.67 | 1.95 | -0.28 |
| Martin ratioReturn relative to average drawdown | 3.82 | 4.28 | -0.46 |
Loading charts...
Drawdowns
EBF vs. BMY - Drawdown Comparison
The maximum EBF drawdown since its inception was -73.10%, roughly equal to the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for EBF and BMY.
Loading charts...
Drawdown Indicators
| EBF | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -73.10% | -72.03% | -1.07% |
Max Drawdown (1Y)Largest decline over 1 year | -11.14% | -12.53% | +1.39% |
Max Drawdown (3Y)Largest decline over 3 years | -22.80% | -36.02% | +13.22% |
Max Drawdown (5Y)Largest decline over 5 years | -22.80% | -47.67% | +24.87% |
Max Drawdown (10Y)Largest decline over 10 years | -35.32% | -47.67% | +12.35% |
Current DrawdownCurrent decline from peak | -4.57% | -16.20% | +11.63% |
Average DrawdownAverage peak-to-trough decline | -20.54% | -22.37% | +1.83% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.89% | 5.73% | -0.84% |
Volatility
EBF vs. BMY - Volatility Comparison
The current volatility for Ennis, Inc. (EBF) is 7.92%, while Bristol-Myers Squibb Company (BMY) has a volatility of 8.93%. This indicates that EBF experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| EBF | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.92% | 8.93% | -1.01% |
Volatility (6M)Calculated over the trailing 6-month period | 17.35% | 18.73% | -1.38% |
Volatility (1Y)Calculated over the trailing 1-year period | 22.42% | 27.76% | -5.34% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.51% | 24.28% | -2.77% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 26.07% | 25.37% | +0.70% |
Dividends
EBF vs. BMY - Dividend Comparison
EBF's dividend yield for the trailing twelve months is around 6.00%, more than BMY's 4.36% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.36% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
EBF Ennis, Inc. | 4.80% | 5.55% | 16.60% | 4.56% | 4.51% | 4.86% | 5.04% | 4.16% | 4.94% | 3.61% | 11.67% | 3.64% |
Financials
EBF vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Ennis, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
EBF vs. BMY - Profitability Comparison
EBF - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Ennis, Inc. reported a gross profit of 31.08M and revenue of 98.62M. Therefore, the gross margin over that period was 31.5%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.
EBF - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Ennis, Inc. reported an operating income of 13.59M and revenue of 98.62M, resulting in an operating margin of 13.8%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.
EBF - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Ennis, Inc. reported a net income of 9.88M and revenue of 98.62M, resulting in a net margin of 10.0%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.
Frequently Asked Questions
EBF and BMY have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BMY has higher volatility (8.93%) compared to EBF (7.92%). In terms of maximum drawdown, EBF dropped -73.10% vs BMY's -72.03%.
BMY currently has the higher Sharpe Ratio (0.88 vs 0.83), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for EBF and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer